<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7367788\results\search\testTrace\results.xml">
  <result pre="other parts of the world. This quick spread of SARS-CoV-2" exact="infection" post="to many states across the globe affecting many people"/>
  <result pre="the global economy. SARS-CoV-2 has a high potential to cause" exact="infection" post="with a higher transmission rate in comparison to SARS-CoV"/>
  <result pre="the spread of COVID-19 are based on the paradigm of" exact="social distancing," post="which includes identification of cases, tracing the contacts, and"/>
  <result pre="the paradigm of social distancing, which includes identification of cases," exact="tracing" post="the contacts, and restrict them to quarantine and isolation."/>
  <result pre="identification of cases, tracing the contacts, and restrict them to" exact="quarantine" post="and isolation. The current pharmacological therapy given is only"/>
  <result pre="immunologically directed strategies and anti-cytokine therapy is indispensable in SARS-CoV-2" exact="infection" post="as a notable proportion of COVID-19 patients have reported"/>
  <result pre="and MERS-CoV, it has become the seventh coronavirus that causes" exact="infection" post="in human beings. The receptor-binding domain present in the"/>
  <result pre="respiratory distress syndrome Pipeline Pharmacological Therapies for COVID-19 Research for" exact="testing" post="the safety and efficacy of different types of interventions"/>
  <result pre="medicine have been investigated so far in search of new" exact="treatment" post="avenues or interventions to combat COVID-19. Among them, remdesivir,"/>
  <result pre="(atorvastatin) have been studied in clinical trials along with standard" exact="treatment" post="regimen. Various antineoplastic drugs (etoposide, methotrexate, melphalan, isotretinoin plus"/>
  <result pre="RNA synthesis and mRNA capping Chronic hepatitis C virus (HCV)" exact="infection" post="Galidesivir (antiviral, adenosine nucleoside analog) Phase 1 Target and"/>
  <result pre="inhibits protein cleavage and halt virus maturation Approved for HIV-1" exact="infection" post="Darunavir (antiviral, protease inhibitor) and Cobicistat (Pharmacokinetic enhancer) Phase"/>
  <result pre="cell counts) Approved as second- generation protease inhibitors for HIV" exact="infection" post="Umifenovir or Arbidol (antiviral, fusion inhibitor) Phase 4 Inhibits"/>
  <result pre="membrane Approved in Russia and China for the prophylaxis and" exact="treatment" post="of influenza A, B, and other arboviruses Danoprevir (antiviral,"/>
  <result pre="viral entry, replication and its release Approved for prophylaxis and" exact="treatment" post="of influenza A (including H1N1) and B Camostat Mesylate"/>
  <result pre="was well tolerated in a phase 3 study for the" exact="treatment" post="of EBOLA virus disease [17]. Currently, remdesivir is one"/>
  <result pre="under trial and is the center of attention for the" exact="treatment" post="of COVID-19. It acts as an RdRp inhibitor and"/>
  <result pre="vitro and animal studies [19, 20]. The published report of" exact="treatment" post="of first COVID-19 patients in the USA and remdesivirâ€™s"/>
  <result pre="a larger population size with an early start of remdesivir" exact="treatment" post="in COVID-19 patients. Moreover, the adequate dose should be"/>
  <result pre="It has been approved in Japan and China for the" exact="treatment" post="of novel influenza virus infections, and in March 2020,"/>
  <result pre="favipiravir with arbidol has shown better recovery profile after 7-day" exact="treatment" post="in those on favipiravir among moderately ill patients but"/>
  <result pre="has shown efficacy against the SARS-CoV-2 virus in vitro, but" exact="treatment" post="with LPV/RTV alone for 14Â days in an open-label"/>
  <result pre="the remarkable clinical improvement, yet WHO and other organizations are" exact="testing" post="the efficacy of LPV/RTV in the clinical trial of"/>
  <result pre="authors also reported that including azithromycin with HCQ for the" exact="treatment" post="of 6 patients has shown more improvements in viral"/>
  <result pre="between HCQ (400Â mg, daily for 5Â days) plus standard" exact="treatment" post="group (supportive care, interferon, and other antivirals) and standard"/>
  <result pre="treatment group (supportive care, interferon, and other antivirals) and standard" exact="treatment" post="alone group [41]. At the time, HCQ was the"/>
  <result pre="India, HCQ is used as a prophylactic drug for SARS-CoV-2" exact="infection" post="in healthcare professionals. Recently, the results of a most"/>
  <result pre="300 COVID-19 patients treated with convalescent plasma along with standard" exact="treatment" post="in a clinical trial conducted in China (ChiCTR2000029757) [51]."/>
  <result pre="the pivotal role of traditional Chinese medicines (TCM) in the" exact="treatment" post="or prevention of many viral infections including influenza, SARS,"/>
  <result pre="ACE2 receptor and exerting an antiviral effect to prevent SARS-CoV-2" exact="infection" post="[70]. Medical institutions in China have published many TCM"/>
  <result pre="herbal medicines for lung clearing and detoxification in the clinical" exact="treatment" post="[69]. On February 17, The National Health Commission (NHC)"/>
  <result pre="et.al has highlighted the possible role of Ayurveda in the" exact="treatment" post="of COVID-19 through psychoneuroimmune pathways [75]. Several compounds known"/>
  <result pre="(Yashtimadhu) might be considered for prophylaxis and as an add-on" exact="treatment" post="for COVID-19 [76, 77]. Many medicinal compounds and natural"/>
  <result pre="date. Several strategies have been employed to target the COVID-19" exact="treatment" post="regimen, and three major strategies that are targeted nowadays"/>
  <result pre="trials are underway in search of a targeted and efficacious" exact="treatment" post="for COVID-19; however, certain barriers have limited the results"/>
  <result pre="2020. 2020. 6.ZhangWZhaoYZhangFWangQLiTLiuZet al.The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
  <result pre="coronavirusesSci Transl Med20179120 16.De WitEFeldmannFCroninJJordanROkumuraAThomasTProphylactic and therapeutic remdesivir (GS-5734 )" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
  <result pre="AK, Zingman BS, Kalil AC, et al. Remdesivir for the" exact="treatment" post="of Covid-19â€&quot;preliminary report. N Engl J Med. 2020:1â€&quot;12. 25.Goldman"/>
  <result pre="D, Chen J, Shu D, Xia J, et al. Experimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control study. Engineering."/>
  <result pre="on the pharmacokinetic and pharmacodynamic properties of drugs considered for" exact="testing" post="in human efficacy trialsClin Pharmacokinet20165590792326798032 31.MadelainVGuedjJMentreFHuyenTJacquotFOLet al.Favipiravir pharmacokinetics in"/>
  <result pre="fever virusesAntimicrob Agents Chemother201761112 32.ChuCMChengVCCHungIFNWongMMLChanKHchuChanKet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsRespir Infect200459252256 33.De"/>
  <result pre="of interferon beta-1b , lopinavirâ€&quot;ritonavir , and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19 : an"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res20132330030223208422 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a"/>
  <result pre="Res20132330030223208422 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005211015631631 39.GaoJTianZYangXBreakthrough: Chloroquine phosphate has shown apparent"/>
  <result pre="spreadVirol J2005211015631631 39.GaoJTianZYangXBreakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends202014727332074550 40.Gautret"/>
  <result pre="L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open- label non-randomized clinical"/>
  <result pre="Agents. 2020. 10.1016/j.ijantimicag.2020.105949. 41.JunCHENDanpingLIULiLIUPingLIUQingnianXULXet al.A pilot study of hydroxychloroquine in" exact="treatment" post="of patients with moderate COVID-19Zhejiang Da Xue Xue Bao"/>
  <result pre="Articles Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysis. Lancet. 2020:1â€&quot;10. Available"/>
  <result pre="T, Sun W, Wang D, Fu B, et al. Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab. chinaXiv. 2020;. 60.HammerQRÃ¼ckertTRomagnaniCNatural"/>
  <result pre="basis for the recognition of Herpes simplex virus type 1" exact="infection" post="by human natural killer cellsFront Immunol201891829403488 62.AraseHMocarskiESCampbellAEHillABLanierLLDirect recognition of"/>
  <result pre="the crisisAm J Chin Med20073557558117708624 69.YangYIslamMSWangJLiYChenXTraditional Chinese medicine in the" exact="treatment" post="of patients infected with 2019-new coronavirus (SARS-CoV-2): a review"/>
 </snippets>
</snippetsTree>
